Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology company Proteonomix has announced the commencement of UMK-121 study with the screening of end stage liver disease patients.
Subscribe to our email newsletter
The University of Medicine & Dentistry of New Jersey together with the company screened the around 30 patients for the inclusion or exclusion in the study.
Proteonomix chief executive officer Michael Cohen said so far 30 patients have been screened based on the inclusion and exclusion criteria approved by the Institutional Review Board as part of the protocol.
"The initiation of screening is the first step towards commencement of the clinical trial of UMK-121," Cohen added.